SEARCH

SEARCH BY CITATION

References

  • 1
    Hosgood G. Canine hemangiosarcoma. Compend Cont Educ Pract Vet 1991;13:10651075.
  • 2
    Hammer AS, Couto CG. Diagnosing and treating canine hemangiosarcoma. Vet Med 1992;87:188201.
  • 3
    Ogilvie GK, Moore AS. Hemangiosarcoma. In: OgilvieGK, MooreAS, eds. Managing the Veterinary Cancer Patient; A Practice Manual. Trenton , NJ : Veterinary Learning Systems; 1995: 367376.
  • 4
    Brown NO, Patnaik AK, MacEwen EG. Canine hemangiosarcoma: Retrospective analysis of 104 cases. J Am Vet Med Assoc 1985; 186:5658.
  • 5
    Adam YG, Huvos AG, Hajdu SI. Malignant vascular tumors in the liver. Ann Surg 1972;175:375383.
  • 6
    Withrow SJ, MacEwen EG. Hemangiosarcoma. In: WithrowSJ, MacEwenEG, eds. Small Animal Clinical Oncology. Philadelphia , PA : WB Saunders; 1996: 521528.
  • 7
    Rebar A., Han FF, Halliwell WH, et al. Microangiopathic hemolyticanemia associated with radiation induced hemangiosarcoma. Vet Pathol 1980;17:443454.
  • 8
    Aronsohn M. Cardiac hemangiosarcoma in the dog: A review of 38 cases. J Am Vet Med Assoc 1985;187:922926.
  • 9
    Wykes PM, Rouse GP, Orton EC. Removal of five canine cardiac tumors using a stapling instrument. Vet Surg 1986;15:103106.
  • 10
    Ward H., Fox LE, Calderwood-Mays MB, et al. Cutaneous hemangiosarcoma in 25 dogs; a retrospective study. J Vet Intern Med 1994;8:345348.
  • 11
    Parchman MB, Crameri FM. Primary vertebral hemangiosarcoma in a dog. J Am Vet Med Assoc 1989;194:7981.
  • 12
    Morrison WB. Blood vascular, lymphatic and splenic cancer. In: MorrisonWB, ed. Cancer in Dogs and Cats: Medical and Surgical Management. Baltimore , MD : Williams and Wilkins; 1998: 705715.
  • 13
    Waters DJ, Hayden DW, Walter PA. Intracranial lesions in dogs with hemangiosarcoma. J Vet Intern Med 1989;3:222230.
  • 14
    Srebernik N., Appleby EC. Breed prevalence and sites of haemangioma and haemangiosarcoma in dogs. Vet Rec 1991;129:408409.
  • 15
    Pharr JW, Holmberg DL, Clark EG. Hemangiosarcoma in the main pulmonary artery of a dog. Vet Radiol Ultrasound 1992;33:7882.
  • 16
    Ohler C., Mughannam A., Reinke JD, et al. Transient hemi-in-attention in a dog with metastatic renal hemangiosarcoma. J Am Anim Hosp Assoc 1994;30:207212.
  • 17
    Crow SE, Bell TG, Wortman JA. Hematuria associated with renal hemangiosarcoma in a dog. J Am Vet Med Assoc 1980;176:531533.
  • 18
    Johnson KA, Powers BE, Withrow SJ, et al. Splenomegaly in dogs; predictors of neoplasia and survival after splenectomy. J Vet Intern Med 1989;3:160166.
  • 19
    Wood CA, Moore AS, Gliatto JM, et al. Prognosis for dogs with stage I or II splenic hemangiosarcoma treated by splenectomy alone: 32 cases (1991–1993). J Am Anim Hosp Assoc 1998;34:417421.
  • 20
    Berg J. Pericardial disease and cardiac neoplasia. Semin Vet Med Surg 1994; 9:185191.
  • 21
    Dunning D., Monnet E., Orton EC, et al. Analysis of prognostic indicators for dogs with pericardial effusion: 46 cases (1985–1996). J Am Vet Med Assoc 1998;212:12761280.
  • 22
    Kerstetter KK, Krahwinkel DJ, Mills DL, et al. Pericardectomy in dogs: 22 cases (1978–1994). J Am Vet Med Assoc 1997;211:736740.
  • 23
    Hargis AM, Ihrke PJ, Spangler WL, et al. A retrospective clinicopathologic study of 212 dogs with cutaneous hemangioma and hemangiosarcoma. Vet Pathol 1992;29:316328.
  • 24
    Hammer AS, Couto CG, Filppi J., et al. Efficacy and toxicity of VAC chemotherapy (vincristine, doxorubicin, and cyclophosphamide) in dogs with hemangiosarcoma. J Vet Intern Med 1991;5:160166.
  • 25
    Sorenmo KA, Jeglum KA, Helfand SC. Chemotherapy of canine hemangiosarcoma with doxorubicin and cyclophosphamide. J Vet Intern Med 1993;7:370376.
  • 26
    Ogilvie GK, Powers BE, Mallinckrodt CH, et al. Surgery and doxorubicin in dogs with hemangiosarcoma. J Vet Intern Med 1996; 10:379384.
  • 27
    de Madron E., Helfand SC, Stebbins KE. Use of chemotherapy for treatment of cardiac hemangiosarcoma in a dog. J Am Vet Med Assoc 1987;190:887891.
  • 28
    Vail DM, Hershey AE, Kurzman ID, et al. Inhalation chemotherapy as an adjuvant therapy in the micrometastasis setting: Proof of principle. Veterinary Cancer Society 18th Annual Meeting, Estes Park, CO, 1998.
  • 29
    Vail DM. Liposomal encapsulation in veterinary oncology. American College of Veterinary Internal Medicine 17th Annual Veterinary Medical Forum, Chicago, IL, 1999.
  • 30
    Vail DM, Kravis LD, Cooley AJ, et al. Preclinical trial of doxorubicin entrapped in sterically stabilized liposomes in dogs with spontaneously arising malignant tumors. Cancer Chemother Pharmacol 1997;39:410416.
  • 31
    Waters DJ, Caywood DD, Hayden DW, et al. Metastatic pattern in a dog with splenic hemangiosarcoma: Clinical implications. J Small Anim Pract 1988;19:805814.
  • 32
    Moore AS, Kirk C., Cardona A. Intracavitary cisplatin chemotherapy with six dogs. J Vet Intern Med 1991;5:227231.
  • 33
    Chun R., Knapp DW, Widmer WR, et al. Phase II clinical trial of carboplatin in canine transitional cell carcinoma of the urinary bladder. J Vet Intern Med 1997;11:279283.
  • 34
    O'Dwyer PJ, Johnson SW, Hamilton TC. Cisplatin and its analogues. In: DeVitaVTJr, HellmanS., RosenbergSA, eds. Cancer: Principles and Practice of Oncology, 5th ed. Philadelphia , PA : Lippincott-Raven; 1997: 418432.
  • 35
    Vail DM, MacEwen EG, Kurzman ID, et al. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: A randomized multi-institutional clinical trial. Clin Cancer Res 1995;1:11651170.
  • 36
    MacEwen EG, Kurzman ID, Rosenthal RC, et al. Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide. J Natl Cancer Inst 1989;81:935938.
  • 37
    Fedler IJ. Molecular biology of cancer: Invasion and metastasis. In: DevitaVTJr, HellmanS., RosenbergSA, eds. Cancer: Principles and Practice of Oncology, 5th ed. Philadelphia , PA : Lippincott-Raven; 1997: 135152.
  • 38
    Folkman J. Clinical applications of research on angiogenesis. Seminars in Medicine of the Beth Israel Hospital, Boston, MA. 1995;333:17571763.
  • 39
    Ogilvie GK. Clinical inhibitors of metalloproteinases and angiogenesis. American College of Veterinary Internal Medicine 17th Annual Veterinary Medical Forum, Chicago, IL, 1999.
  • 40
    Angiogenesis inhibitors in clinical trials. National Cancer Institute cancerTrials Web site. Available at: http:cancertrials.nci.nih.govnewsangiotable.html. Accessed September 20, 1999.
  • 41
    Boehm T., Folkman J., Browder T., et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997;390:404407.
  • 42
    Nelson NJ. Inhibitors of angiogenesis enter phase III testing. J Natl Cancer Inst 1998;90:960963.
  • 43
    White CW. Treatment of hemangiomatosis with recombinant interferon alfa. Semin Hematol 1990;27:1522.
  • 44
    Greinwald JH, Burke DK, Bonthius DJ, et al. An update on the treatment of hemangiomas in children with interferon alfa-2a. Arch Otolaryngol Head Neck Surg 1999;125:2127.
  • 45
    Tamayo L., Ortiz DM, Orozco-Covarrubias L., et al. Therapeutic efficacy of interferon alfa-2b in infants with life-threatening giant hemangiomas. Arch Dermatol 1997;133:15671571.
  • 46
    Chang E., Boyd A., Nelson CC, et al. Successful treatment of infantile hemangiomas with interferon-alpha-2b. J Pediatr Hematol Oncol 1997;19:237244.
  • 47
    Folkman J. Tumor angiogenesis and tissue factor. Nat Med 1996;2:167168.
  • 48
    Fujimoto M., Kiyosawa T., Murata S., et al. Vascular endothelial growth factor in human angiosarcoma. Anticancer Res 1998;18:37253730.
  • 49
    Allen DK, Waters DJ, Knapp DW, et al. High urine concentrations of basic fibroblast growth factor in dogs with bladder cancer. J Vet Intern Med 1996;10:231234.
  • 50
    Oberg K., Alm G. The incidence and clinical significance of antibodies to interferon-a in patients with solid tumors. Biotherapy 1997;10:15.
  • 51
    McKenna RM, Oberg KE. Antibodies to interferon-alpha in treated cancer patients: Incidence and significance. J Interferon Cytokine Res 1997;17:141143.
  • 52
    Rebuck JA, Fish DN. Thalidomide revisited. AIDS Reader 1998;8:79.
  • 53
    Kruse FE, Joussen AM, Rohrschneider K., et al. Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefes Arch Clin Exp Ophthalmol 1998;236:461466.
  • 54
    Minchinton AI, Fryer KH, Wendt KR, et al. The effect of thalidomide on experimental tumors and metastases. Anticancer Drugs 1996;7:339343.
  • 55
    Jankowski M., Fulton L., Sheafor S., et al. Ongoing evaluation of single agent thalidomide in dogs with measurable cancer. Veterinary Cancer Society 19th Annual Meeting, Wood's Hole, MA, 1999.
  • 56
    Joseph IB, Isaacs JT. Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents. J Natl Cancer Inst 1998;90:16481653.
  • 57
    Yarchoan R. Therapy for Kaposi's sarcoma: Recent advances and experimental approaches. J Acquir Immune Defic Syndr 1999; 21: S66S73.
  • 58
    Burton E., Prados M. New chemotherapy options for the treatment of malignant gliomas. Curr Opin Oncol 1999;11:157161.
  • 59
    Curran S., Murray GI. Matrix metalloproteinases in tumour invasion and metastasis. J Pathol 1999;189:300308.
  • 60
    Yu AE, Hewitt RE, Connor EW, et al. Matrix metalloproteinases. Novel targets for directed cancer therapy. Drugs Aging 1997;11:229244.
  • 61
    Jones JL, Walker RA. Control of metalloproteinase activity in cancer. J Pathol 1997;183:377379.
  • 62
    Lana SE, Hansen RA, Sanderson KR, et al. Matrix metalloproteinases in serum and plasma of normal and tumor bearing dogs. Veterinary Cancer Society 18th Annual Meeting, Estes Park, CO, 1998.
  • 63
    Cockett MI, Murphy G., Birch ML, et al. Matrix metalloproteinases and metastatic cancer. Biochem Soc Symp 1998;63:295313.
  • 64
    Wojtowicz-Praga SM, Dickson RB, Hawkins MJ. Matrix metalloproteinase inhibitors. Invest New Drugs 1997;15:6175.
  • 65
    Denis LJ, Verweij J. Matrix metalloproteinase inhibitors: Present achievements and future prospects. Invest New Drugs 1997;15:175185.
  • 66
    Jones JL, Walker RA. Control of matrix metalloproteinase activity in cancer. J Pathol 1997;183:377379.
  • 67
    Drummond AH, Beckett P., Brown PD, et al. Preclinical and clinical studies of MMP inhibitors in cancer. Ann N Y Acad Sci 1999; 878:228235.
  • 68
    Leibman N., Lana SE, Hansen RA, et al. Identification of matrix metalloproteinases in canine mast cell tumors. Veterinary Cancer Society 18th Annual Meeting, Estes Park, CO, 1998.
  • 69
    Bahl T., Lehmann H., Rudolph R. Matrix metalloproteinases: A useful prognostic indicator in canine mammary cancer? Veterinary Cancer Society 18th Annual Meeting, Estes Park, CO, 1998.
  • 70
    Lana SE, Ogilvie GK, Hansen RA, et al. Matrix metalloproteinsases levels as a predictor of early treatment failure in dogs with lymphoma. Veterinary Cancer Society 19th Annual Meeting, Wood's Hole, MA, 1999.
  • 71
    Paria BC, Kitchell BE, Bamn RG, et al. Molecular cloning and expression of MMP-9 from canine fibrosarcoma. Veterinary Cancer Society 19th Annual Meeting, Wood's Hole, MA, 1999.
  • 72
    Gilbertson-Beadling S., Powers EA, Stamp-Cole M., et al. The tetracycline analogs minocycline and doxycycline inhibit angiogenesis in vitro by a non-metalloproteinase-dependent mechanism. Cancer Chemother Pharmacol 1995;36:418424.
  • 73
    Teicher BA, Sotomayor EA, Huang ZD. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 1992;52:67026704.
  • 74
    Weingart JD, Sipos EP, Brem H. The role of minocycline in the treatment of intracranial 9L glioma. J Neurosurg 1995;82:635640.
  • 75
    Parangi S., O'Reilly M., Christofori G., et al. Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc Natl Acad Sci USA 1996;93:20022007.
  • 76
    Soremno KA, Duda L., Barber L., et al. Treatment of canine hemangiosarcoma with conventional chemotherapy and an antiangiogenic agent. Veterinary Cancer Society 16th Annual Meeting, Pacific Grove, CA, 1996.
  • 77
    Ogilvie GK. Interventional nutrition for the cancer patient. Clin Tech Small Anim Pract 1998; 13:224231.
  • 78
    Ogilvie GK, Moore AS. Nutritional support. In: OgilvieGK, MooreAS, eds. Managing the Veterinary Cancer Patient: A Practice Manual. Trenton , NJ : Veterinary Learning Systems; 1995: 124127.
  • 79
    Ogilvie GK, Walters LM, Salman MD, et al. Treatment of dogs with lymphoma with Adriamycin and a diet high in carbohydrate or high in fat. Am J Vet Res 1994;8:95104.
  • 80
    Ogilvie GK, Vail DM. Nutrition and cancer: Recent developments. Vet Clin North Am Small Anim Pract 1990;20:969985.
  • 81
    Kern KA, Norton JA. Cancer cachexia. J Parenter Enter Nutr 1988;12:286298.
  • 82
    Heber D., Byerley LO, Chi J., et al. Pathophysiology of malnutrition in the adult cancer patient. Cancer 1986;58:18671873.
  • 83
    Vail DM, Ogilvie GK, Wheeler SL, et al. Alterations in carbohydrate metabolism in canine lymphoma. J Vet Intern Med 1990;4:811.
  • 84
    Howard J., Senior DE. Cachexia and nutritional issues in animals with cancer. J Am Vet Med Assoc 1999;214:632637.
  • 85
    Ogilvie GK. Antimetastasis therapy: The future is now. American College of Veterinary Internal Medicine 16th Annual Veterinary Medicine Forum, San Diego, CA, 1998.
  • 86
    Hahn KA. Integrins: The next tumor target? American College of Veterinary Internal Medicine 17th Annual Veterinary Medicine Forum, Chicago, IL, 1999.
  • 87
    Hahn KA, Daniel GB. Molecular strategies for targeted tumor imaging. Vet Cancer Soc Newsl 1999; 23: 1, 4–5.